Editorial: Learning from failure

Nature Reviews Drug Discovery

Volumn 9, Issue 7, 2010, Pages 499-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DIMEBON; MELANOCORTIN 4 RECEPTOR; INDOLE DERIVATIVE; NOOTROPIC AGENT;

ALZHEIMER DISEASE; CLINICAL STUDY; DATA BASE; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG RESEARCH; EDITORIAL; FOOD AND DRUG ADMINISTRATION; INFORMATION PROCESSING; PARKINSON DISEASE; PEER REVIEW; PRIORITY JOURNAL; PUBLICATION; WEIGHT REDUCTION; BIBLIOGRAPHIC DATABASE; CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT FAILURE;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DATABASES, BIBLIOGRAPHIC; INDOLES; NOOTROPIC AGENTS; TREATMENT FAILURE;

EID: 79958026811     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3222     Document Type: Editorial

References (2)

1. The evolution of trial registration. Nature Rev. Drug Discov. 8, 755 (2009).
2. Krishna, R. et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin. Pharmacol. Ther. 86, 659-666 (2009).